PHASE-II CLINICAL-TRIAL OF HIGH-DOSE RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR

被引：3

作者：

LENK, H ^{[1
]}

TANNEBERGER, S ^{[1
]}

MULLER, U ^{[1
]}

EBERT, J ^{[1
]}

SHIGA, T ^{[1
]}

机构：

[1] ASAHI CHEM IND CO LTD,DEPT RES & DEV,TOKYO,JAPAN

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1989年 / 24卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：391 / 392

页数：2

共 5 条

[1] ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].

CARSWELL, EA ;

OLD, LJ ;

KASSEL, RL ;

GREEN, S ;

FIORE, N ;

WILLIAMSON, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670

[2]

CREAVEN PJ, 1987, CANCER CHEMOTH PHARM, V20, P137

[3] PHASE-I STUDY OF RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR [J].

KIMURA, K ;

TAGUCHI, T ;

URUSHIZAKI, I ;

OHNO, R ;

ABE, O ;

FURUE, H ;

HATTORI, T ;

ICHIHASHI, H ;

INOGUCHI, K ;

MAJIMA, H ;

NIITANI, H ;

OTA, K ;

SAITO, T ;

SUGA, S ;

SUZUOKI, Y ;

WAKUI, A ;

YAMADA, K .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1987, 20 (03) :223-229

[4]

LENK H, 1988, Archiv fuer Geschwulstforschung, V58, P89

[5]

TANNEBERGER S, 1987, IMMUNOBIOLOGY, V175, P38

← 1 →